Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 6/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.46 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | LAP3 | P28838 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4931761 | 1.00 | S1PR2 (0.46) | S1PR2S1PR1S1PR3S1PR4ZDHHC7 | |
| SCHEMBL28682838 | 1.00 | S1PR2 (0.46) | S1PR2S1PR1S1PR3S1PR4ZDHHC7 | |
| SCHEMBL3223213 | 0.98 | TP53 (0.44) | S1PR2S1PR1S1PR3S1PR4ZDHHC7 | |
| SCHEMBL1140577 | 0.98 | TP53 (0.44) | S1PR2S1PR1S1PR3S1PR4ZDHHC7 | |
| SCHEMBL4934729 | 0.93 | CYP1A2 (0.42) | S1PR2S1PR1S1PR3S1PR4ALDH1A1 | |
| SCHEMBL11421457 | 0.88 | NAAA (0.56) | S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL8770739 | 0.88 | NAAA (0.56) | S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL28245451 | 0.88 | CPB2 (0.53) | ALDH1A1 | |
| SCHEMBL30998049 | 0.88 | NAAA (0.47) | S1PR2S1PR1S1PR3S1PR4ZDHHC7 | |
| SCHEMBL28410817 | 0.86 | CYP1A2 (0.53) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312080-A1 | Novel dioctatin derivatives and production process thereof | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2008-12-18 | — | — | US | disclosed |
| CN-1043125-A | Be used as the aryl urea of the replacement of high-potency sweetener | NUTRASWEET CO (US) | 1990-06-20 | — | — | CN | disclosed |
| WO-1990002112-A1 | SUBSTITUTED ARYL UREAS AS HIGH POTENCY SWEETENERS | THE NUTRASWEET COMPANY (US) | 1990-03-08 | — | — | WO | disclosed |
| EP-0355819-A1 | Substituted aryl ureas as high potency sweeteners | THE NUTRASWEET COMPANY (a Delaware corporation) (US) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312080-A1 | Novel dioctatin derivatives and production process thereof | AKR7A2, HDHD5, DECR1 | S1PR2 4302/4885S1PR1 4602/4885S1PR3 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.